Literature DB >> 7037037

Severe oral lichen planus: treatment with an aromatic retinoid (etretinate).

K Hersle, H Mobacken, K Sloberg, H Thilander.   

Abstract

A double-blind study of twenty-eight patients with severe oral lichen planus treated with etretinate (75 mg daily) or a placebo for 2 months, showed that the oral retinoid had a marked beneficial effect. Nine non-responders who had received only placebo then entered an open cross-over study and they responded well to etretinate. Etretinate thus provided effective symptomatic relief for severe oral lichen planus, but side-effects were common, and six patients stopped treatment because of them.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7037037     DOI: 10.1111/j.1365-2133.1982.tb00904.x

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  6 in total

Review 1.  Treatment of lichen planus.

Authors:  G F Oliver; R K Winkelmann
Journal:  Drugs       Date:  1993-01       Impact factor: 9.546

Review 2.  The retinoids. A review of their clinical pharmacology and therapeutic use.

Authors:  C E Orfanos; R Ehlert; H Gollnick
Journal:  Drugs       Date:  1987-10       Impact factor: 9.546

Review 3.  Etretinate. A review of its pharmacological properties and therapeutic efficacy in psoriasis and other skin disorders.

Authors:  A Ward; R N Brogden; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1983-07       Impact factor: 9.546

Review 4.  Synthetic retinoids in dermatology.

Authors:  E H Heller; N J Shiffman
Journal:  Can Med Assoc J       Date:  1985-05-15       Impact factor: 8.262

5.  Interventions for treating oral lichen planus: corticosteroid therapies.

Authors:  Giovanni Lodi; Maddalena Manfredi; Valeria Mercadante; Ruth Murphy; Marco Carrozzo
Journal:  Cochrane Database Syst Rev       Date:  2020-02-28

6.  Oral lichen planus: comparative efficacy and treatment costs-a systematic review.

Authors:  Shaiba Sandhu; Brittany A Klein; Malak Al-Hadlaq; Prazwala Chirravur; Amal Bajonaid; Yuanming Xu; Rossella Intini; Mai Hussein; Piamkamon Vacharotayangul; Herve Sroussi; Nathaniel Treister; Stephen Sonis
Journal:  BMC Oral Health       Date:  2022-05-06       Impact factor: 3.747

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.